Risk of lung cancer decreases drastically within 5 years of quitting smoking

quit smoking
The risk of lung cancer significantly drops within five years of quitting smoking. Research shows that former smokers experience a marked decline in lung cancer risk compared to current smokers. This underscores the importance and benefits of smoking cessation for long-term health and cancer prevention.

Share This Post

The latest research and analysis of the landmark Framingham Heart Study by researchers at Vanderbilt University Medical Center suggest that the risk of lung cancer is drastically increased within 5 years of quitting smoking. World No Tobacco Day was observed throughout the world, looking at the adverse effects of smoking. Notably, smoking effects almost all 100 types of cancer in humans. The National Heart, Lung, and Blood Institute supported the study, which contributed to identifying high blood pressure and high cholesterol as major cardiovascular disease risk factors. But it also tracked cancer outcomes.

Smoking and lung cancer

The current study looked at 8,907 participants who had been followed for 25 to 34 years. During this period, 284 lung cancers were diagnosed, nearly 93 percent of which occurred among heavy smokers, those who had smoked at least a pack of cigarettes a day for 21 years or more. Five years after quitting, the risk of developing lung cancer in former heavy smokers dropped by 39 percent compared to current smokers, and continued to fall as time went on. Yet even 25 years after quitting, their lung-cancer risk remained over threefold higher compared to people who had never smoked.

I hope this new study motivates people to quit smoking as soon as possible. Let’s come together and take a pledge on this World No Tobacco Day to educate smokers on the ill effects of smoking.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy for AIDS related B Cell malignancies
Aids cancer

CAR T Cell therapy for AIDS related B-Cell malignancies

CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient’s T cells to express chimeric antigen receptors (CARs) targeting CD19 on B cells. This treatment holds promise in eradicating malignant B cells but must carefully manage immunosuppression in HIV-positive individuals.

Cancer statistics in India 2024
Cancer

Cancer statistics in India 2024: Incidence, estimates and projections

In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most prevalent among women and men, respectively. Sadly, many cases are diagnosed late, impacting survival rates. Improved awareness and access to healthcare are crucial. By 2030, cancer incidence is expected to surpass 1.7 million cases annually. Efforts to enhance prevention, early detection, and treatment access are crucial to mitigate this growing burden. Check our cancer statistics in India for 2024 and future projections.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
Need help with cancer treatment?
Scan the code
Hello,
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy